Can the dual-functional capability of CIK cells be used to improve antitumor effects?

Cellular Immunology

Volumn 287, Issue 1, 2014, Pages 18-22

  Wang, Xiaomeng ^a   Yu, Wenwen ^a   Li, Hui ^a   Yu, Jinpu ^a   Zhang, Xinwei ^a   Ren, Xiubao ^a   Cao, Shui ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cytokine induced killer (CIK) cells; Immunotherapy; Natural killer (NK) cells; T cells; Tumor immunology

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; CELL POPULATION; CELL SURFACE; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; HUMAN; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MONONUCLEAR PHAGOCYTE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR CELL;

ADCC; ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELLS; APCS; CIK; CYTOKINE-INDUCED KILLER (CIK) CELLS; CYTOKINE-INDUCED KILLER CELLS; DC; DENDRITIC CELL; IMMUNOTHERAPY; KILLER IMMUNOGLOBULIN-LIKE RECEPTORS; KIR; LAK; LYMPHOKINE ACTIVATED KILLER CELLS; NATURAL KILLER (NK) CELLS; NATURAL KILLER CELLS; NK; T CELLS; TIL; TUMOR IMMUNOLOGY; TUMOR-INFILTRATING LYMPHOCYTES CELLS;

ANIMALS; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES;

EID: 84890854644     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.11.009     Document Type: Review

References (55)

1. Archimbaud E., Bailly M., Dore J.F. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance. Br. J. Haematol. 1991, 77:328-334.
2. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., White D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 1994, 86:1159-1166.
3. Hui K.M. CIK cells-current status, clinical perspectives and future prospects-the good news. Expert Opin. Biol. Ther. 2012, 12:659-661.
4. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J. Cancer 2011, 2:363-368.
5. Hontscha C., Borck Y., Zhou H., Messmer D., Schmidt-Wolf I.G. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol. 2011, 137:305-310.
6. Niu Q., Wang W., Li Y., Qin S., Wang Y., Wan G., Guan J., Zhu W. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int. Immunopharmacol. 2011, 11:449-456.
7. Wu C., Jiang J., Shi L., Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res. 2008, 28:3997-4002.
8. Shi L., Zhou Q., Wu J., Ji M., Li G., Jiang J., Wu C. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol. Immunother. 2012, 61:2251-2259.
9. Ma Y., Zhang Z., Tang L., Xu Y.C., Xie Z.M., Gu X.F., Wang H.X. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 2012, 14:483-493.
10. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., Weissman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med. 1991, 174:139-149.
11. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 1994, 153:1687-1696.
12. + CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118:3301-3310.
13. Lanier L.L. NK cell receptors. Annu. Rev. Immunol. 1998, 16:359-393.
14. Cheng M., Ma J., Chen Y., Zhang J., Zhao W., Wei H., Ling B., Sun R., Tian Z. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line. Cell Transplant. 2011, 20:1731-1746.
15. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., Biassoni R., Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 2001, 19:197-223.
16. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., Yokoyama W.M., Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
17. Bottino C., Biassoni R., Millo R., Moretta L., Moretta A. The human natural cytotoxicity receptors (NCR) that induce HLA class I-independent NK cell triggering. Hum. Immunol. 2000, 61:1-6.
18. Cantoni C., Bottino C., Vitale M., Pessino A., Augugliaro R., Malaspina A., Parolini S., Moretta L., Moretta A., Biassoni R. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J. Exp. Med. 1999, 189:787-796.
19. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 2003, 3:781-790.
20. Chalupny N.J., Sutherland C.L., Lawrence W.A., Rein-Weston A., Cosman D. ULBP4 is a novel ligand for human NKG2D. Biochem. Biophys. Res. Commun. 2003, 305:129-135.
21. Vankayalapati R., Garg A., Porgador A., Griffith D.E., Klucar P., Safi H., Girard W.M., Cosman D., Spies T., Barnes P.F. Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium. J. Immunol. 2005, 175:4611-4617.
22. Wu J., Cherwinski H., Spies T., Phillips J.H., Lanier L.L. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J. Exp. Med. 2000, 192:1059-1068.
23. Huntington N.D., Vosshenrich C.A., Di Santo J.P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 2007, 7:703-714.
24. Braud V.M., Allan D.S., O'Callaghan C.A., Soderstrom K., D'Andrea A., Ogg G.S., Lazetic S., Young N.T., Bell J.I., Phillips J.H., Lanier L.L., McMichael A.J. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391:795-799.
25. Vivier E., Nunes J.A., Vely F. Natural killer cell signaling pathways. Science 2004, 306:1517-1519.
26. Bour-Jordan H., Bluestone J.A. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol. Rev. 2009, 229:41-66.
27. Paterson A.M., Vanguri V.K., Sharpe A.H. SnapShot: B7/CD28 costimulation. Cell 2009, 137. pp. 974-974 e971.
28. Pages F., Ragueneau M., Rottapel R., Truneh A., Nunes J., Imbert J., Olive D. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 1994, 369:327-329.
29. Gonzalez S., Groh V., Spies T. Immunobiology of human NKG2D and its ligands. Curr. Top. Microbiol. Immunol. 2006, 298:121-138.
30. Tang F., Chen Z., Ciszewski C., Setty M., Solus J., Tretiakova M., Ebert E., Han J., Lin A., Guandalini S., Groh V., Spies T., Green P., Jabri B. Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15. J. Exp. Med. 2009, 206:707-719.
31. Verneris M.R., Karami M., Baker J., Jayaswal A., Negrin R.S. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004, 103:3065-3072.
32. Schmidt-Wolf I.G., Lefterova P., Mehta B.A., Fernandez L.P., Huhn D., Blume K.G., Weissman I.L., Negrin R.S. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp. Hematol. 1993, 21:1673-1679.
33. Lu X., Zhu A., Cai X., Jia Z., Han W., Ma L., Zhou M., Qian K., Cen L., Chen B. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells. Cancer Biol. Ther. 2012, 13:623-629.
34. Mesiano G., Todorovic M., Gammaitoni L., Leuci V., Giraudo Diego L., Carnevale-Schianca F., Fagioli F., Piacibello W., Aglietta M., Sangiolo D. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Exp. Opin. Biol. Ther. 2012, 12:673-684.
35. Franceschetti M., Pievani A., Borleri G., Vago L., Fleischhauer K., Golay J., Introna M. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp. Hematol. 2009, 37. pp. 616-628 e612.
36. Li H., Wang C., Yu J., Cao S., Wei F., Zhang W., Han Y., Ren X.B. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 2009, 11:1076-1083.
37. Vitale M., Della Chiesa M., Carlomagno S., Pende D., Arico M., Moretta L., Moretta A. NK-dependent DC maturation is mediated by TNFalpha and IFN gamma released upon engagement of the NKp30 triggering receptor. Blood 2005, 106:566-571.
38. Linn Y.C., Lau S.K., Liu B.H., Ng L.H., Yong H.X., Hui K.M. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology 2009, 126:423-435.
39. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 2005, 23:225-274.
40. Johnson P., Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol. 2003, 30:3-8.
41. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003, 21:3940-3947.
42. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., Watier H., Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004, 64:4664-4669.
43. Ravetch J.V., Bolland S. IgG Fc receptors. Annu. Rev. Immunol. 2001, 19:275-290.
44. Sangiolo D., Martinuzzi E., Todorovic M., Vitaggio K., Vallario A., Jordaney N., Carnevale-Schianca F., Capaldi A., Geuna M., Casorzo L., Nash R.A., Aglietta M., Cignetti A. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int. Immunol. 2008, 20:841-848.
45. Baker J., Verneris M.R., Ito M., Shizuru J.A., Negrin R.S. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001, 97:2923-2931.
46. Sumitran S., Anderson P., Widner H., Holgersson J. Porcine embryonic brain cell cytotoxicity mediated by human natural killer cells. Cell Transplant. 1999, 8:601-610.
47. Osada T., Nagawa H., Kitayama J., Tsuno N.H., Ishihara S., Takamizawa M., Shibata Y. Peripheral blood dendritic cells, but not monocyte-derived dendritic cells, can augment human NK cell function. Cell Immunol. 2001, 213:14-23.
48. + cell-derived NK cell cytotoxicity by dendritic cells. J. Immunol. 2001, 166:1590-1600.
49. Gerosa F., Baldani-Guerra B., Nisii C., Marchesini V., Carra G., Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 2002, 195:327-333.
50. Ferlazzo G., Tsang M.L., Moretta L., Melioli G., Steinman R.M., Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 2002, 195:343-351.
51. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
52. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997, 90:3245-3287.
53. Yang L., Ren B., Li H., Yu J., Cao S., Hao X., Ren X. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol. Immunother. 2012.
54. Braakman E., van de Winkel J.G., van Krimpen B.A., Jansze M., Bolhuis R.L. CD16 on human gamma delta T lymphocytes: expression, function, and specificity for mouse IgG isotypes. Cell Immunol. 1992, 143:97-107.
55. Kohrt H.E., Houot R., Marabelle A., Cho H.J., Osman K., Goldstein M., Levy R., Brody J. Combination strategies to enhance antitumor ADCC. Immunotherapy 2012, 4:511-527.